Top

Published in:

01-10-2018 | Original Article

Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer

Authors: Qin Li, Tielong Tang, Peng Zhang, Chenlu Liu, Yan Pu, Yan Zhang, Huizi Song, Yanyun Wang, Yaping Song, Min Su, Bin Zhou, Lin Zhang

Published in: Familial Cancer | Issue 4/2018

Abstract

Interleukin-31 is a crucial cytokine triggering inflammation which could be one of the risk factors of tumors. However, data for correlation between IL-31 and tumors are limited. The purpose of our study was to discuss whether genetic polymorphisms of IL-31 were associated with the susceptibility and clinical outcomes of bladder cancer. Our study enrolled 478 controls, 156 non-muscle-invasive bladder cancer (NMIBC) and 138 muscle-invasive bladder cancer (MIBC) patients. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping two single nucleotide polymorphisms (SNPs) of IL-31 gene including rs7977932 and rs4758680. Our results showed that A allele and CA/AA genotypes of rs4758680 were associated with susceptibility to bladder cancer (P = 0.04, OR 1.32, 95% CI 1.01–1.72, and P = 0.02, OR 1.43, 95% CI 1.05–1.96, respectively), and G allele of rs7977932 might be a protect factor for tobacco smoking patients compared with non-smoking patients (P = 0.005, OR 0.42, 95% CI 0.23–0.76). Furthermore, CA/AA genotypes of rs4758680 might be the independent risk factors for the decreased recurrence-free survival of the patients with MIBC (P = 0.03, OR 2.02, 95% CI 1.06–3.85. Our data indicated that polymorphisms of IL-31 are associated with bladder cancer, and rs4758680 could be an independent prediction for MIBC patients with a high risk of recurrence.

El-Arabey AA (2017) New insight for metformin against bladder cancer. Genes Environ 39:13. https://doi.org/10.1186/s41021-017-0074-z CrossRefPubMedPubMedCentral

Zhang Y, Sun Y, Chen T et al (2014) Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population. Int J Mol Sci 15(11):19330–19341. https://doi.org/10.3390/ijms151119330 CrossRefPubMedPubMedCentral

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):9CrossRef

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA 65(1):5–29 https://doi.org/10.3322/caac.21254 CrossRefPubMed

Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241. https://doi.org/10.1016/j.eururo.2012.07.033 CrossRefPubMed

Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V (2010) Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 193(2):131–137CrossRef

Sonkoly E, Muller A, Lauerma AI et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411–417CrossRef

Cornelissen C, Luscher-Firzlaff J, Baron JM, Luscher B (2012) Signaling by IL-31 and functional consequences. Eur J Cell Biol 91(6–7):552–566CrossRef

10.

Knight D, Mutsaers SE, Prele CM (2011) STAT3 in tissue fibrosis: is there a role in the lung? Pulm Pharmacol Ther 24(2):193–198CrossRef

11.

Ouyang H, Cheng J, Zheng Y, Du J (2014) Role of IL-31 in regulation of Th2 cytokine levels in patients with nasal polyps. Eur Archiv Oto-rhino-laryngol 271(10):2703–2709. https://doi.org/10.1007/s00405-014-2913-x CrossRef

12.

Tseng WN, Lo MH, Guo MM, Hsieh KS, Chang WC, Kuo HC (2014) IL-31 associated with coronary artery lesion formation in Kawasaki disease. PloS ONE 9(8):e105195. https://doi.org/10.1371/journal.pone.0105195 CrossRefPubMedPubMedCentral

13.

Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW (2010) Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22(6):453–467. https://doi.org/10.1093/intimm/dxq027 CrossRefPubMed

14.

Yagi Y, Andoh A, Nishida A et al (2007) Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med 19(6):941–946PubMed

15.

Lan CC, Tu HP, Wu CS et al (2011) Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population. Exp Dermatol 20(12):975–979. https://doi.org/10.1111/j.1600-0625.2011.01374.x CrossRefPubMed

16.

Huang HT, Chen JM, Guo J, Lan Y, Wei YS (2016) The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol Int 36(6):799–805. https://doi.org/10.1007/s00296-016-3422-6 CrossRefPubMed

17.

Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW (2007) Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology 122(4):532–541. https://doi.org/10.1111/j.1365-2567.2007.02668.x CrossRefPubMedPubMedCentral

18.

Zeng X, Zhang Z, Gao QQ et al (2016) Clinical significance of serum interleukin-31 and interleukin-33 levels in patients of endometrial cancer: a case control study. Dis Markers 2016:9262919 https://doi.org/10.1155/2016/9262919 CrossRefPubMedPubMedCentral

19.

Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2012) Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Exp Oncol 34(4):348–353PubMed

20.

Hirao Y, Kim WJ, Fujimoto K (2009) Environmental factors promoting bladder cancer. Curr Opin Urol 19(5):494–499CrossRef

21.

Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22(15):1928–1929CrossRef

22.

Dupont WD, Plummer WD Jr. (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11(2):116–128CrossRef

23.

Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A (2014) International variations in bladder cancer incidence and mortality. Eur Urol 66(1):59–73. https://doi.org/10.1016/j.eururo.2013.10.001 CrossRefPubMed

24.

Gandini S, Botteri E, Iodice S et al (2008) Tobacco smoking and cancer: a meta-analysis. Int J Cancer 122(1):155–164. https://doi.org/10.1002/ijc.23033 CrossRefPubMed

25.

Vineis P, Talaska G, Malaveille C et al (1996) DNA adducts in urothelial cells:relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 65(3):314–316. https://doi.org/10.1002/(SICI)1097-0215(19960126)65:3<314::AID-IJC6>3.0.CO;2-2 CrossRefPubMed

26.

Corral R, Lewinger JP, Van Den Berg D et al (2014) Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int J Cancer 135(2):335–347. https://doi.org/10.1002/ijc.28693 CrossRefPubMedPubMedCentral

27.

Cornelissen C, Brans R, Czaja K et al (2011) Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells. Br J Dermatol 165(5):966–975CrossRef

28.

Niyonsaba F, Ushio H, Hara M et al (2010) Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 184(7):3526–3534CrossRef

29.

Ishii T, Wang J, Zhang W et al (2009) Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 113(23):5942–5950PubMed

30.

Siraganian RP (2003) Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol 15(6):639–646CrossRef

31.

Bilsborough J, Leung DY, Maurer M et al (2006) IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117(2):418–425CrossRef

32.

Raap U, Wichmann K, Bruder M et al (2008) Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122(2):421–423. https://doi.org/10.1016/j.jaci.2008.05.047 CrossRefPubMed

33.

Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y (2008) Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 14(33):5154–5161CrossRef

34.

Dambacher J, Beigel F, Seiderer J et al (2007) Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 56(9):1257–1265CrossRef

35.

Lei Z, Liu G, Huang Q et al (2008) SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 63(3):327–332CrossRef

36.

Okano M, Fujiwara T, Higaki T et al (2011) Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis. J Allergy Clin Immunol 127(1):277-9, 279.e1-11. https://doi.org/10.1016/j.jaci.2010.09.029 CrossRef

37.

Malek M, Glen J, Rebala K et al (2015) Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. Acta Derm Venereol 95(3):283–288. https://doi.org/10.2340/00015555-1958 CrossRefPubMed

38.

Nattkemper LA, Martinez-Escala ME, Gelman AB et al (2016) Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol 96(7):894–898. https://doi.org/10.2340/00015555-2417 CrossRefPubMed

39.

Ferretti E, Tripodo C, Pagnan G et al (2015) The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia 29(4):958–967. https://doi.org/10.1038/leu.2014.291 CrossRefPubMed

40.

Lange M, Glen J, Zablotna M et al (2017) Interleukin-31 polymorphisms and serum IL-31 level in patients with mastocytosis: correlation with clinical presen-tation and pruritus. Acta Derm Venereol 97(1):47–53. https://doi.org/10.2340/00015555-2474 CrossRefPubMed

41.

Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95(3):497–505. https://doi.org/10.1002/jcb.20477 CrossRefPubMed

42.

Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W (2008) Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 19(5–6):347–356. https://doi.org/10.1016/j.cytogfr.2008.08.003 CrossRefPubMedPubMedCentral

43.

Rizner TL (2016) Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Rev Mol Diagn 16(12):1315–1336. https://doi.org/10.1080/14737159.2016.1258302 CrossRefPubMed

Title: Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer
Authors: Qin Li
Tielong Tang
Peng Zhang
Chenlu Liu
Yan Pu
Yan Zhang
Huizi Song
Yanyun Wang
Yaping Song
Min Su
Bin Zhou
Lin Zhang
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-017-0060-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk

Feasibility of endoscopic resection using bipolar snare for nonampullary duodenal tumours in familial adenomatous polyposis patients

Letter to the editor

Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience

Discussions about predictive genetic testing for Lynch syndrome: the role of health professionals and families in decisions to decline

SNP association study in PMS2-associated Lynch syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer